19 October-1 December 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
E-posters
EP01-Resisting the resistance
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP01-Resisting the resistance
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP01-100-21-Pharmacokinetics of anti-TB drugs in multidrug-resistant TB patients in IndiaA pharmacokinetic (PK) study of drugs used to treat multidrug-resistant (MDR) tuberculosis (TB) was undertaken in 350 adult MDR-TB patients treated according to the prevailing guidelines in India. Factors influencing drug PK and end of intensive phase status were also determined. Results of this study will be discussed.
Agibothu Kupparam Hemanth Kumar

EP01-101-21-Multidrug-resistant TB and its determinants of health service, community and social context in the state of São Paulo, BrazilThis study presents the social determinants of health in relation to the occurrence of multidrug-resistant tuberculosis, key information for disease control in regions with great social inequity. We emphasise the importance of socioeconomic, demographic and health system structure conditions for the spread of the disease.
Ricardo Arcêncio

EP01-102-21-Decentralised care for rifampicin-resistant TB in Western Cape, South Africa: a laboratory cohort studySouth Africa implemented a policy to decentralise rifampicin-resistant tuberculosis (RR-TB) care in 2011. We used laboratory data from the Western Cape province to assess patterns of RR-TB care and identify changes in hospitalisation rates, length of hospital stay and travel burden from 2012-2014. We compared Cape Town with more rural districts.
Helen Jenkins

EP01-103-21-Effectiveness, safety and feasibility of nine-month treatment regimen for rifampin-resistant TB in the PhilippinesThe short nine-month multidrug-resistant tuberculosis regimen had a high treatment success rate (74 percent) with a favourable safety profile in a prospective single-arm study conducted in the Philippines during 07/2015-12/2016. Nine-month treatment regimen operational research had a major impact on building national capacity and infrastructure for programmatic adoption of the new regimen in country.
Vivian Lofranco

EP01-104-21-Characterising multidrug-resistant tuberculosis transmission in rural KwaZulu-Natal: a prospective cohort studyThis study combined whole genome sequencing of 129 Mycobacterium tuberculosis (Mtb) isolates with demographic data from patients with multidrug-resistant TB in KwaZulu-Natal, South Africa. Transmission clusters based on genomic differences were identified. Relationships between demographic characteristics, Mtb lineage, rpoB mutation and transmission clustering were examined, aiming to elucidate drivers of Mtb transmission.
Cassandra Fairhead

EP01-105-21-Effectiveness and safety of use of bedaquiline and delamanid in combination for drug-resistant extrapulmonary TB in Mumbai, IndiaMédecins Sans Frontières has been providing treatment, including bedaquiline and/or delamanid, to patients with drug-resistant tuberculosis (TB) in Mumbai since 2015. Cases are referred with complex resistance profiles and extensive treatment history. This study aims to describe the effectiveness and safety of use of bedaquiline and delamanid for drug-resistant extrapulmonary TB.
Himani Mongia

EP01-106-21-Eliciting patient preferences for different attributes of a community-based model for management of multidrug-resistant TB in Uganda: a discrete choice experimentThe advent of all-oral regimens for the management of multidrug- resistant tuberculosis makes the implementation of home-based treatment a possibility for this group of patients. However, to be successful, options for home-based care should take into consideration patient preferences for different aspects of care.    
Stella Zawedde-Muyanja

EP01-107-21-Treatment of multidrug-resistant TB with modified shorter all-oral treatment regimen: Belarus operational research studyIn October 2018, Belarus started to use mSTR for multidrug-resistant tuberculosis under operational research conditions. By 1st May 2020, 415 patients were included in the study and, of them, 114 had final treatment outcomes with encouraging results (89% of treatment success).
Alena Skrahina

EP01-108-21-Patient’s perspective on drug-resistant TB medication: does it matter? Putting research into action to develop information, education and communication materialA qualitative study of drug-resistant tuberculosis (DR-TB) treatment from the perspective and experience of patient, family, healthcare worker and psychologist in six health facilities within three districts of Indonesia as a basis for developing DR-TB information, education and communication material based on the Health Belief Model and Transtheoretical Model.
Ferdiana Yunita

EP01-109-21-The role of clinical healthcare champions in driving drug-resistant TB policy implementation in South AfricaIn South Africa, champions have emerged as a driving force behind the implementation of decentralised management of drug-resistant tuberculosis (DR-TB). This study explored the typology of champions in the decentralisation of DR-TB management, strategies that champions used to implement policy and the contextual factors that enabled or hindered their agency.
Sacha Le Roux

Loading...
E-posters
EP09-Improved acceptability of TB regimens needed
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP09-Improved acceptability of TB regimens needed
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP09-176-21-Risk factors for cycloserine neurotoxicity in patients treated for multidrug-resistant TBCycloserine has been re-classified as a category B drug by the World Health Organization. The neurotoxicity associated with cylcoserine has limited its use in treatment programmes. We systemically collected neurotoxicity data in patients in Cape Town treated with cycloserine, dosed as terizidone, for multidrug-resistant TB. We then evaluated factors, including cycloserine AUC, with neurotoxicity.
Richard Court

EP09-177-21-Hearing loss on second line injectable therapy for rifampin-resistant TB in a retrospective cohort in Worcester, South AfricaSecond line injectables (SLIs) remain a part of the drug-resistant TB regimen in many settings globally, even with SLI-induced ototoxicity rates remaining high. In this South African rifampin-resistant TB cohort, regimen adjustments due to hearing loss were common, further emphasising the need for access to SLI-sparing regimens.
Tara C Bouton

EP09-178-21-Treatment outcome of shorter regimen for multidrug-resistant TB in Pakistan 2018The National Tuberculosis (TB) Programme in Pakistan recommended a shorter regimen of nine-11 months in January 2018 under programmatic settings in all PMDT sites of the country. We compared treatment outcome of patients who were put on the shorter regimen, with those who were eligible for the shorter regimen but who were put on the longer one.
Abdul Ghafoor

EP09-179-21-From pilot to nationwide scale-up of shorter treatment regimen for drug-resistant TB treatment: lessons from NigeriaFollowing the adoption and rapid scale-up of GeneXpert as a primary tuberculosis (TB) diagnostic tool, limited bed spaces resulted in the challenge of a huge number of diagnosed drug-resistant TB (DR-TB) patients on treatment waiting lists. The CTB project facilitated nationwide scale-up of STR and NDs, including establishing aDSM for newly diagnosed DR-TB patients.
Sani Useni

EP09-180-21-Preferences for shorter regimens and child-friendly formulations for TB preventive treatment among families affected by TB in Lima, PeruFocus group discussions with families affected by tuberculosis (TB) in Lima, Peru, explored preferences for TB preventive treatment regimens, for both adult and child contacts, and sought to understand the drivers behind these preferences.
Courtney Yuen

EP09-182-21-Safety and efficacy of allogeneic γδ T cells for multidrug-resistant TB: an interim analysis of a prospective single centre, open labeled, non-randomised, controlled matched trialAnti-tuberculosis (TB) drugs for multidrug-resistant (MDR-TB) and rifampicin-resistant TB (RR-TB) currently encounter many obstacles and host-directed therapy approaches are now a focus for use as adjunct treatment options for shortening duration, limiting immunopathology, and improving outcomes. The safety and efficacy of γδT cells have been studied in our pilot trial, which is the first one worldwide.
Liang Fu

EP09-183-21-Interim outcomes of bedaquiline-containing regimen for the treatment of MDR/XDR-TB — a prospective cohort study from Hunan, ChinaChina introduced bedaquiline relatively late and little data exists on its use outside clinical trials. We conducted  a prospective cohort study to evaluate the effectiveness and safety of bedaquiline-containing regimen for 24 weeks intensive treatment of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis (MDR/XDR-TB) in Hunan province, China.
li shi

EP09-184-21-Treatment interruption patterns among patients on bedaquiline- containing regimen under programmatic conditionsThis was an observational study, including 275 consecutively enrolled tuberculosis (TB) patients, who received a bedaquiline-containing regimen under the national TB programme in India. The study analysed the reasons for interruptions of treatment and loss to follow-up and their effect on interim treatment outcomes during the first six months of treatment.
Rupak Singla

EP09-185-21-Incidence rate of linezolid adverse events among Myanmar adult MDR/RR-TB patients on individualised longer drug-resistant TB regimensLinezolid, a Group A drug, has evidences for significant treatment success but it also has common, serious adverse events such as myelosuppression and peripheral neuropathy. The study determined the incidence rate of linezolid adverse events and characterised the safety of linezolid among Myanmar adult multidrug-resistant and rifampicin-resistant tuberculosis (TB) patients who were on individualised, longer drug-resistant TB regimens.
Thandar Hmun

EP09-186-21-Real-time payment of Nikshay Poshan Yojana under direct benefit transfer scheme improved overall notification, treatment adherence and outcome of TB and DR-TB patients in Odisha, IndiaReal-time payment of Nikshay Poshan Yojana under a direct benefit transfer scheme improved the overall notification, treatment adherence and outcome of tuberculosis (TB) and drug-resistant TB patients in Odisha, India. The National TB Programme performance rank in the Odisha state went up from 27th to 15th during 2019.
Gayadhar Mallick

Loading...
Channel 1
SS-03-Approaches to improve TB case finding and treatment outcomes in children
event_note
Loading...
query_builder 09:45 - 10:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-03-Approaches to improve TB case finding and treatment outcomes in children
*Please scroll down for more information*
Organised by: Johnson & Johnson Global Public Health

Confirming the diagnosis of tuberculosis (TB) is a major challenge, especially in very young children. For drug-resistant TB, this means that children may end up on suboptimal therapy or even on no therapy at all.
Researchers around the world have explored how to improve the diagnosis of TB in children. In this satellite session, we plan to facilitate the sharing of learnings from paediatric TB experts on how healthcare providers and  national TB programmes can improve the identification of children with TB so that they receive appropriate care.

09:45 - 10:00: Epidemiology of childhood TB and drug-resistant TB Prof Seddon will describe the current epidemiology of childhood tuberculosis

James Seddon

10:00 - 10:15: Symptom-based approach to diagnosing childhood TB. What next? Variable presentations of tuberculosis (TB) among children present a unique challenge. In many instances, objective diagnostic  modalities (eg sputum culture or molecular methods) are suboptimal so physicians have to rely on 'clinical' judgement,  supplemented by epidemiological information, to make a diagnosis. Canwe do better?

Ben Marais

10:15 - 10:30: Research agenda to improve TB treatment outcomes in children The world has made some progress in the treatment of drug-resistant tuberculosis (DR-TB) disease. It is imperative that children not be  just a footnote to this progress, but that they are included in efforts to find more effective and better tolerated drug regimen for DR-TB. 
Prof Hesseling will discuss current gaps in the treatment of childhood DR-TB, some of the ongoing research activities to address these gaps  and the way forward to ensure that children benefit from advances in the treatment of DR-TB.

Anneke Hesseling

10:30 - 10:45: Challenges in diagnosing and treating TB in children Children have been neglected in the fight against tuberculosis (TB). Despite being the number one infectious disease killer, TB does  not feature on the child survival agendas. There is need to elevate childhood TB to the top of the agenda and we do what  needs to be done to ensure that no child unnecessarily dies from TB, if we truly intend to eliminate TB.

Farhana Amanullah

Loading...
E-posters
EP17-Facing TB during the COVID-19 pandemic
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP17-Facing TB during the COVID-19 pandemic
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP17-263-22-Overcoming challenges of sample transportation for TB testing during COVID-19 lock down, March-April 2020: an interventional study in Telangana, IndiaThe diagnostic services in tuberculosis (TB) were hampered during the COVID-19 lock down. This in turn will reduced early detection of drug-resistant TB. By utilising the available resources, such as the 104 ambulance vans at district level, the challenge of sample transportation and, thus diagnosis, of drug-resistant TB has been addressed.
sumalata Chittiboyina

EP17-264-22-TB patients through telecommunication in COVID-19 situation: BRAC experienceEvery day around 600 COVID-19 cases are diagnosed, which may increase if sample testing capacity can increase. The world is fighting to end infectious diseases. Planned and effective utilisation of resources can ensure uninterrupted tuberculosis (TB) service. However, to increase TB cases finding in a lock down situation is very challenging.
Md Abul Khair Basher

EP17-265-22-Physically distant but still in contact: telephonic counselling for rifampicin-resistant TB patients in South Africa during the COVID-19 pandemicCOVID-19 threatens to undermine progress in the global tuberculosis (TB) response by disrupting routine TB services. Here, we describe telephonic counselling offered to rifampicin-resistant TB (RR-TB) patients in South Africa during the COVID-19 pandemic. Some early benefits include support to address patients’ adherence problems and reduced patient costs in seeking RR-TB care.
Erika Mohr-Holland

EP17-266-22-Programmatic adaptations to the treatment of rifampicin-resistant TB infection in children and adolescents during COVID-19Post-exposure management services were modified in view of COVID-19. The strategy for recalling asymptomatic contacts was revised. Contacts identified as high risk were screened and initiated on treatment during a home visit or at a facility with infection control practices. Multi-month medication refills were provided; follow-up was conducted telephonically.
Erika Mohr-Holland

EP17-267-22-Collaboration in TB and COVID-19 control in Bungoma CountyThe World Health Organization (WHO) declared novel COVID-19 as a global pandemic. COVID-19 has several health system challenges which directly or indirectly affect tuberculosis (TB) services. Complementary COVID-19 and TB response is critical during this pandemic. Both diseases can utilise the capacity building efforts, surveillance and monitoring systems put in place.
Paul Lodi

EP17-268-22-Connecting the DOTS during the COVID-19 pandemic: using community structures and the private sector to establish linkages for increased TB case detection in NigeriaTo optimise social and behaviour change (SBC) efforts amidst COVID-19 restrictions and to sustain tuberculosis (TB) case identification and service delivery in the private sector, SHOPS Plus Nigeria (Sustaining Health Outcomes through the Private Sector) adjusted its SBC strategy to a community-led approach, comprised of patent and proprietary medicine vendors, community structures (mosques and churches) and private clinics.
Ayodele Iroko

Loading...
Channel 2
SP-15-Short, all-oral regimens for rifampicin-resistant TB: progress towards programmatic implementation at country level.
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-15-Short, all-oral regimens for rifampicin-resistant TB: progress towards programmatic implementation at country level.
*Please scroll down for more information*
In March 2019, the World Health Organization (WHO) consolidated guidelines on rifampicin-resistant tuberculosis (RR-TB) included the recommendation that modified all-oral regimens to treat RR-TB should be adopted under operational research conditions.  Based on newly available data, the WHO released a Rapid Communication in December 2019 that recommended a specific all-oral, bedaquiline-containing regimen for programmatic use.  This workshop shares insights from countries that have early programmatic or operational research experience with all-oral shorter RR-TB treatment regimens, with particular focus on implementation planning and interim treatment outcomes.  

11:00 - 11:05: Introduction

11:05 - 11:17: Early adoption of a modified, all-oral shorter rifampicin-resistant TB regimen with group A and group B drugs in GeorgiaGiven a high prevalence of intolerance/confirmed resistance to several drugs in the standardised, injectable-based shorter regimen, Georgia initiated guideline revisions and protocol development after the World Health Organization consolidated guidelines in December 2018. In addition to guidance for longer, all-oral rifampicin-resistant TB regimens, national guidelines recommend a modified, all-oral shorter regimen (mSTR) of bedaquiline/linezolid/levofloxacin/clofazimine/cycloserine for nine months, with delamanid substitution for toxicities.  The guidelines and protocol were submitted to the Ministry of Health in January 2019, approved in June 2019, and fully implemented the same month.  To ensure rapid transition, drug quantification and ordering, along with training for all clinicians and staff, took place in parallel to approval processes.  While national policy allows use of mSTR programmatically, Georgia is committed to evidence generation as part of the World Health Organization Euro’s operational research initiative. As of April 2020, 106 patients have received mSTR; 17 have completed treatment with cure, 2 lost to follow-up, and 87 remain on treatment.
Nino Lomtadze

11:17 - 11:29: Rapid implementation of an all-oral, shorter rifampicin-resistant TB regimen during the COVID-19 pandemic in the PhilippinesTo improve on successful treatment outcomes of 58% in patients with rifampicin-resistant tuberculosis (RR-TB) in 2016, the Philippines introduced the standardised, injectable-based shorter regimen (SSTR) in January 2017 under programme conditions.  Treatment success of 68% for patients receiving the SSTR in 2017, revealed high rates of lost to follow up primarily due to adverse events from the injectable agent.  The national TB control programme met in January 2020 to plan the transition to an all-oral,shorter regimen based on the World Health Organization's December 2019 Rapid Communication; a departmental memorandum in February 2020 mandated all health facilities providing drug-resistant TB services to implement a standardised, shorter, all-oral bedaquiline based RR-TB regimen (SSOR) by 1 March 2020. Additional orientation and training on the guideline update were provided March-April 2020. Despite the evolving COVID-19 pandemic, within one month from release of local guidelines, there are more than 150 patients enrolled on SSOR in the Philippines.
Mary Rosary Santiago

11:29 - 11:41: Adopting best practices in rifampicin-resistant TB management in Zambia: implementation of WHO recommendations for all-oral RR-TB regimensOf the 507 patients started on treatment in Zambia in 2018, 357 (70%) started on the 2016 World Health Organization (WHO) recommended standardised shorter regimen, 132 (26%) started on a longer, conventional regimen, and 18 (4%) started on an individualised regimen with bedaquiline. By the end of second quarter 2019, 60% of all patients started on rifampicin-resistant TB (RR-TB) treatment were receiving a fully oral, bedaquiline-based longer regimen.  The National TB Programme of Zambia has kept pace with WHO recommendations, most recently with an addendum to the national RR-TB guidelines, finalised in September 2019, with immediate plans to phase out the injectable- based shorter regimen and move to fully-oral regimens for a majority of newly diagnosed RR-TB patients. By the start of 2020, all RR-TB patients are being commenced on injectable-free regimens. This presentation will describe the subsequent transition from injectable agents to bedaquiline, within the shorter regimen, from the perspective of clinicians and patients. 
Patrick Lungu

11:41 - 11:53: Impact of the COVID-19 pandemic on full implementation of all-oral shorter RR-TB regimens in PakistanThe National TB Programme (NTP) is among the lead countries with prompt implementation of World Health Organization (WHO) rifampicin- resistant/multidrug-resistant TB(RR/MDR-TB) recommendations and guidelines whenever required. The all-oral, longer treatment regimen containing bedaquiline was initiated in July 2019, with over 900 patients having received bedaquiline by December 2019. Following the issuing of WHO's Rapid Communication on the use of an all-oral, shorter treatment regimen in the same month, the NTP subsequently circulated an advisory in January 2020 to start enrolling eligible patients on a shorter regimen containing bedaquiline instead of amikacin. The advisory was immediately put into implementation at all 33 PMDT sites across the country. However, due to the emergence of the current COVID-19 pandemic in Pakistan, enrolments on the all-oral, shorter regimen have not met full potential and the pandemic response is seen as a huge challenge in optimum implementation.  
Abdul Ghafoor

11:53 - 12:20: Q&A session

Loading...
Channel 2
OA-13-The race for improved multidrug-resistant care
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-13-The race for improved multidrug-resistant care
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-13-577-22-Best practices in bedaquiline and delamanid use for rifampicin- resistant TB management: implementation of extension and combination use in 43 high burden countries Results from the #StepUpforTB 2020 study show 69% of countries recommend the combination use of bedaquiline and delamanid, while only 40% allow routine extension of either drug.  While policy recommendations for the newer drugs have included younger ages, adoption of best practices in bedaquiline and delamanid for adults remains slow.

Tiziana Masini

12:43 - 12:51: OA-13-578-22-The decentralised drug-resistant TB programme in South Africa: from policy to implementation A policy, supporting decentralised drug-resistant TB (DR-TB) treatment provision in South Africa, has had variable implementation. This paper examined how content, actors and processes of policy have interacted in context-specific ways to inform implementation. A better understanding of policy dynamics will contribute to lessons for strengthening future implementation of DR-TB policy.

Waasila Jassat

12:51 - 12:59: OA-13-579-22-Programmatic management of MDR/XDR-TB patients using the short treatment regimen from 2015 to 2019 in Cameroon Cameroon's programmatic management of rifampicin-resistant and multidrug-resistant tuberculosis (TB) patients, from 2015-2019, showed an 82% (505 out of 706) favourable outcome using the short treatment regimen. Out of 478 (68%) patients with documented data, moderate to severe auditory side effects (57/12%) remain the major challenge. We advocate for closer audiogram monitoring of patients receiving an injectable-base regimen.

Christelle G. Jouego

12:59 - 13:07: OA-13-580-22-Outcomes of a representative sample of patients lost to follow-up during drug-resistant TB treatment in the Philippines We identified additional mortality after tracing drug-resistant tuberculosis (TB) patients lost to follow-up from the Philippines National TB Control Programme. Strategies for retaining patients in care are critical to improving outcomes. Tracing should be considered for reporting accurate mortality data.

Alexander Rupert Lim

13:07 - 13:15: OA-13-581-22-Undiagnosed drug resistance in Mycobacterium tuberculosis is associated with higher mortality in countries with high TB burdens Accurate diagnosis is important in managing and controlling drug-resistant tuberculosis (TB) to reduce mortality. We compared results from drug resistance diagnoses clinics in countries with high TB burdens, against standardised culture-based testing and whole genome sequencing.

Martina L. Reichmuth

13:15 - 13:23: OA-13-582-22-Predominant yield of drug-sensitive TB among contacts of multidrug- resistant TB patients in Uganda: a call for next generation sequencing Contact investigation is one of the key, active tuberculosis (TB) case finding measures for early detection and treatment initiation in order to mitigate transmission and mortality due to delayed treatment. This abstract demonstrates the findings of a contact tracing cascade analysis for multidrug-resistant TB patients in a low-resource setting.

Kenneth Mutesasira

13:23 - 13:31: OA-13-583-22-Achieving high treatment success rate for drug-resistant TB following introduction of the novel, shorter treatment regimen Uganda adopted the novel, shorter multidrug-resistant TB (MDR-TB) treatment regimen following the 2016 World Health Organization MDR-TB treatment guidelines update. We share findings of a high treatment success rate among patients enrolled into the shorter regimen. 

John Paul Otuba

13:31 - 13:39: OA-13-584-22-Introducing facility-based mortality reviews into programmatic management of drug-resistant TB: lessons from Uganda We share findings of patient and health system factors that are contributing to multidrug-resistant tuberculosis patient mortality, following the introduction of facility-based death reviews into the programmatic management of drug-resistant TB in Uganda. 

John Paul Otuba

13:39 - 13:50: Q&A


Loading...
Channel 7
OA-17-Safety first: side effects of old and new drugs
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-17-Safety first: side effects of old and new drugs
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-17-605-22-Audiometry outcomes during and after drug-resistant TB treatment with a kanamycin-containing drug-regimen: drug-resistant TB patients assessed in three rural districts of Masvingo Zimbabwe The abstract focuses on the ototoxic effects of a kanamycin-containing regimen on drug-resistant (DR-TB) patients managed in rural Zimbabwe without previous access to audiometry monitoring. Results show the importance of screening for drug side-effects during, as well as after, stopping the drug.

Cordelia Kunzekwenyika

12:43 - 12:51: OA-17-606-22-Validation study comparing tablet-based and conventional audiometry results in stage 2 of the STREAM trial Due to limited access to conventional audiometry testing in many high TB burden countries, tablet-based audiometry was used to monitor and evaluate for changes in hearing among multidrug-resistant tuberculosis trial participants. This validation study investigates the accuracy of tablet-based audiometry compared to conventional audiometry in stage 2 of the STREAM Trial.

Ishmael Qawiy

12:51 - 12:59: OA-17-607-22-Safety and efficacy of a shorter TB treatment: time to sputum culture positivity as a surrogate marker of bacterial load in an radomised control study of high-dose rifampicin and pyrazinamide Tuberculosis (TB) treatment is long, posing a risk of poor treatment adherence. In this randomised phase II study, we aim to investigate a strategy to shorten TB treatment by exploring safety, drug exposure and efficacy of a high-dose rifampicin/pyrazinamide regimen on early bactericidal activity using time to sputum culture positivity (TTP).

David Ekqvist

12:59 - 13:07: OA-17-608-22-Predictive analyses of QT prolongation from ECG monitoring in STREAM stage 1 The STREAM stage 1 trial investigated a short nine-month regimen for the treatment of multidrug-resistant tuberculosis, which included high-dose moxifloxacin and clofazimine, both of which can lead to QT prolongation. We analysed whether assessment of QT interval early on in treatment could be used to identify patients requiring more intensive QT monitoring.

Gareth Hughes

13:07 - 13:15: OA-17-609-22-A study to determine the frequency of QT interval prolongation in people treated with bedaquiline for drug-resistant TB Bedaquiline (BDQ) is a recent addition to the drug-resistant tuberculosis (DR-TB) armamentarium. There is a black-box warning of arrhythmias and sudden death associated with BDQ therapy. This retrospective study aimed to determine the incidence of QTc prolongation and cardiac events in patients receiving BDQ DR-TB therapy under routine conditions.

Sharon Isralls

13:15 - 13:23: OA-17-610-22-Pretomanid added to bedaquiline and linezolid for patients with extensively-drug resistant TB and multidrug-resistant TB treatment failure or intolerance: a comparison of prospective cohorts The Nix-TB study, evaluating the treatment of 109 patients with highly resistant TB with the oral 3-drug regimen (bedaquiline, pretomanid and linezolid; BPaL) for six-nine months, is compared to a cohort of contemporaneous patients, in South Africa, receiving regimens that included bedaquiline and linezolid, but not pretomanid.

Suzette Oelofse

13:23 - 13:31: OA-17-611-22-Moxifloxacin pharmacokinetics and cardiac safety in children with multidrug-resistant TB In this work, we characterise moxifloxacin pharmacokinetics and the exposure-response relationship with QT-interval prolongation in children 0-17 years. These results are from two observational pharmacokinetic and safety studies and provide important information regarding moxifloxacin use in young (<7 years) children and insight on optimal dosing.

Kendra K Radtke

13:31 - 13:50: Q&A


Loading...
E-posters
EP22-TB adherence to treatment
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP22-TB adherence to treatment
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP22-307-23-Implementation of TB preventive treatment in South Africa: the urgent need to address gapsTuberculosis (TB) and HIV are major global public health concerns. Providing TB preventive treatment (TPT) to people at risk of progressing to TB disease decreases TB transmission and TB-related mortality. We compared TPT initiations and completions between two fiscal years to identify programme gaps.
Katlego Motlhaoleng

EP22-308-23-TB preventive treatment preferences among children in Eswatini: a mixed methods studyUnderstanding preferences regarding tuberculosis preventive treatment (TPT) regimens’ characteristics and service delivery models, is key to efforts to improve TPT initiation and completion. We report on results from a mixed methods study, including a discrete choice experiment and qualitative interviews among children in Eswatini, an African country with high TB burden.
Yael Hirsch-Moverman

EP22-309-23-Low completion rate of once-weekly rifapentine plus isoniazid regimen among elderly populationWith the advanced preventive therapy as a cornerstone of End TB, a better regimen which is easier for elderly contacts to complete is crucial, since interruption of preventive therapy among elderly populations is not improved by providing 3HP.
Pei-Chun Chan

EP22-311-23-Risk based patient-centred strategies for TB treatment. Inference from a prospective cohort studyTo optimise strategies for prevention and management of tuberculosis, (TB) we need to adapt available resources and implement patient-centred approaches. Implementing different treatment strategies considering a patient baseline risk, organisation of healthcare delivery and interventions for social inclusion, will probably result in better TB outcomes in resource-constrained systems.
Fernando Rubinstein

EP22-312-23-Perspectives of multidrug-resistant TB patients on the use of treatment supporters: experience from Lagos, NigeriaA qualitative study to explore the patient perspective when using treatment supporters in multidrug-resistant tuberculosis (MDR-TB) care. From the patients’ perspectives, they found it very supportive and family members were preferred as treatment supporters because of the closeness, and the ability to support, patients emotionally in the course of treatment.
Oluremilekun Kusimo

EP22-313-23-Improving treatment adherence with technology and patient-centred care in MoroccoA comprehensive tuberculosis (TB) management programme using mHealth and patient-centred management was implemented to reduce the rate of patients lost to follow-up in Morocco. Patients who enrolled in the programme showed an improved treatment success rate and the new TB management programme could be applicable in other countries under similar circumstances.
Narae Moon

EP22-314-23-The effect of digital dosing monitoring on the adherence of patients treated for TB in Viet NamNon-adherence is an important risk factor for relapse among patients with tuberculosis (TB). This study evaluated the effect of digital adherence support, using a Medication Event Reminder Monitor (MERM), for outpatients treated for newly diagnosed, smear-positive pulmonary TB in Viet Nam.
Thu-Anh Nguyen

EP22-315-23-Impact of health-related quality of life on treatment adherence during treatment for pulmonary TBThis abstract describes how health-related quality of life, while receiving drug-sensitive tuberculosis (TB) treatment, impacts on treatment adherence. It is part of an ongoing observational cohort study among adult patients receiving treatment for TB through national TB programmes in The Gambia, Mozambique, South Africa and Tanzania. 
Tembeka Sineke

EP22-316-23-Evaluation of the integrated multidrug-resistant and rifampin-resistant TB patient management approach in Wuhan Jinyintan Hospital, Hubei Province, ChinaA retrospective analysis of year-one patient data of three intervention cohorts to evaluate the integrated multidrug-resistant tuberculosis and rifampin-resistant tuberculosis patient management approach implemented in Wuhan Jinyintan Hospital, Hubei Province, China
Qi Nie

EP22-317-23-Peer empowerment to strengthen treatment adherence among multidrug-resistant TB patients: field experience in Shaanxi Province, ChinaPeer empowerment was introduced by Xi'an Chest Hospital's medical staff to provide support to local multidrug-resistant tuberculosis patients in order to enhance treatment adherence. This is the field experience in Xi'an, Shaanxi Province in Western China.
Hui Luo

EP22-318-23-Diverse patterns of TB medication adherence seen via directly observed therapy in an observational cohortWe analysed directly observed therapy (DOT) data from a prospective drug-susceptible tuberculosis (TB) cohort in Worcester, South Africa. Participants were more likely to miss doses during the therapy continuation than the initiation phase. Among those who were 60-90% adherent, there was significant variation in the TB treatment adherence patterns.
Tara C Bouton

Loading...
Processing. Please wait.
Loading...